1
|
Wang X, Yan Y, Gan T, Yang X, Li D, Zhou D, Sun Q, Huang Z, Zhong J. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. Gut 2019; 68:140-149. [PMID: 29180585 DOI: 10.1136/gutjnl-2017-314870] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Revised: 10/26/2017] [Accepted: 11/11/2017] [Indexed: 12/26/2022]
Abstract
OBJECTIVE Despite the development of highly effective direct-acting antivirals, a prophylactic vaccine is needed for eradicating HCV. A major hurdle of HCV vaccine development is to induce immunity against HCV with high genome diversity. We previously demonstrated that a soluble E2 (sE2) expressed from insect cells induces broadly neutralising antibodies (NAbs) and prevents HCV infection. The objective of this study is to develop a multivalent HCV vaccine to increase the antigenic coverage. DESIGN We designed a trivalent vaccine containing sE2 from genotype 1a, 1b and 3a. Mice and rhesus macaques were immunised with monovalent or trivalent sE2 vaccine, and sera or purified immunoglobulin were assessed for neutralisation against a panel of cell culture-derived virion (HCVcc) of genotype 1-7 in cell culture. Splenocytes from the vaccinated macaques were assessed for HCV-specific T cell response. RESULTS We showed that the trivalent vaccine elicited pangenotypic NAbs in mice, which neutralised HCVcc of all the seven genotypes more potently than the monovalent vaccine. Further analyses demonstrated that each sE2 component of this trivalent vaccine elicited unique spectrum of NAbs which acted synergistically to inhibit HCV infection. Finally, the trivalent vaccine triggered stronger and more uniform multigenotypic neutralising antibody response than the monovalent vaccine in rhesus macaques. CONCLUSIONS In summary, we developed a trivalent HCV vaccine that induces broad and synergistic-acting neutralising antibodies in mice and non-human primates.
Collapse
Affiliation(s)
- Xuesong Wang
- Unit of Viral Hepatitis, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.,Unit of Vaccinology and Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| | - Yu Yan
- Unit of Viral Hepatitis, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| | - Tianyu Gan
- Unit of Viral Hepatitis, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| | - Xi Yang
- University of Chinese Academy of Sciences, Beijing, China.,Vaccine Research Center, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China
| | - Dapeng Li
- Unit of Viral Hepatitis, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.,Unit of Vaccinology and Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| | - Dongming Zhou
- University of Chinese Academy of Sciences, Beijing, China.,Vaccine Research Center, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China
| | - Qiang Sun
- University of Chinese Academy of Sciences, Beijing, China.,Suzhou Non-human Primate Facility, Institute of Neuroscience, State Key Laboratory of Neuroscience, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China
| | - Zhong Huang
- Unit of Vaccinology and Antiviral Strategies, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| | - Jin Zhong
- Unit of Viral Hepatitis, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
2
|
Marquez JP, Rivera R, Kang KH, Gardner MB, Torres JV. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression. Viral Immunol 2012; 25:141-52. [PMID: 22486305 DOI: 10.1089/vim.2011.0066] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Human papillomavirus (HPV) is associated with premalignant lesions such as high-grade cervical intraepithelial neoplasia (CIN-III) with potential progression to cervical carcinoma. There are now preventive vaccines against HPV. However, no effective therapeutic vaccine or immunological treatment exists for individuals already infected or for the 470,000 women that develop high-grade dysplasia, carcinoma in situ, and cervical cancer each year. More than half of these women die from cervical cancer. Relative non-immunogenicity of HPV infection is one of the main reasons for the difficulty in designing a comprehensive therapeutic vaccine against HPV-induced premalignant lesions and cervical carcinoma. HPV E6 and E7 proteins, the major HPV oncogenes, are highly immunogenic but fail to induce cross-reactive and protective immune responses against heterologous strains. We designed and synthesized a therapeutic peptide vaccine comprised of multivalent peptide mixtures called hypervariable epitope constructs (HECs) that represent the major epitope variants of the oncogenic E7 structural protein, and assessed their immunogenicity and in vivo efficacy in mice. Our results show that this peptide vaccine can induce strong, HPV-specific, T-helper cell and CTL responses. More significantly, we have demonstrated that the vaccine is efficacious as a therapeutic agent in a mouse HPV tumor model. Therefore, the HPV HEC vaccine approach described herein can potentially prevent progression of HPV-associated premalignant lesions, and may also be therapeutic against tumors associated with HPV.
Collapse
Affiliation(s)
- Juan P Marquez
- Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, California, USA
| | | | | | | | | |
Collapse
|
4
|
Sun LL, Li JT, Wu YZ, Ni B, Long L, Xiang YL, He W, Liang ZQ. Screening and identification of dominant functional fragments of human epididymal protease inhibitor. Vaccine 2010; 28:1847-53. [DOI: 10.1016/j.vaccine.2009.11.080] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2009] [Revised: 11/21/2009] [Accepted: 11/30/2009] [Indexed: 10/20/2022]
|
5
|
Abstract
A major challenge to contemporary peptide chemistry is to reproduce highly complex active sites or complexes of native proteins. In addition to the need for the combination of different peptide fragments, true protein mimics designed for therapeutic use frequently require the incorporation of multiple copies of given active domains in a biologically relevant spatial arrangement. Perhaps the best examples for this line of drug design are subunit vaccine candidates against extracellular domains of ion-channel proteins. One of our earlier constructs containing four copies of the ectodomain of the M2 protein of influenza virus together with two independent T-helper cell epitopes induced protective antibody production in mice. Here I describe an improved synthesis of the M2-based multiepitope and multivalent peptide construct. In general, the synthetic strategy outlined here can serve as a model for the orthogonal N-terminal and side-chain-protecting scheme during the preparation of large, complex peptides or small, engineered proteins.
Collapse
|
6
|
García-Quintanilla A. Overcoming viral escape with vaccines that generate and display antigen diversity in vivo. Virol J 2007; 4:125. [PMID: 18034902 PMCID: PMC2169210 DOI: 10.1186/1743-422x-4-125] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2007] [Accepted: 11/22/2007] [Indexed: 11/11/2022] Open
Abstract
Background Viral diversity is a key problem for the design of effective and universal vaccines. Virtually, a vaccine candidate including most of the diversity for a given epitope would force the virus to create escape mutants above the viability threshold or with a high fitness cost. Presentation of the hypothesis Therefore, I hypothesize that priming the immune system with polyvalent vaccines where each single vehicle generates and displays multiple antigen variants in vivo, will elicit a broad and long-lasting immune response able to avoid viral escape. Testing the hypothesis To this purpose, I propose the use of yeasts that carry virus-like particles designed to pack the antigen-coding RNA inside and replicate it via RNA-dependent RNA polymerase. This would produce diversity in vivo limited to the target of interest and without killing the vaccine vehicle. Implications of the hypothesis This approach is in contrast with peptide cocktails synthesized in vitro and polyvalent strategies where every cell or vector displays a single or definite number of mutants; but similarly to all them, it should be able to overcome original antigenic sin, avoid major histocompatibility complex restriction, and elicit broad cross-reactive immune responses. Here I discuss additional advantages such as minimal global antagonism or those derived from using a yeast vehicle, and potential drawbacks like autoimmunity. Diversity generated by this method could be monitored both genotypically and phenotypically, and therefore selected or discarded before use if needed.
Collapse
|
7
|
Gazarian KG, Gazarian T, Hernández R, Possani LD. Immunology of scorpion toxins and perspectives for generation of anti-venom vaccines. Vaccine 2005; 23:3357-68. [PMID: 15837360 DOI: 10.1016/j.vaccine.2004.12.027] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2004] [Revised: 08/31/2004] [Accepted: 12/22/2004] [Indexed: 10/25/2022]
Abstract
Scorpions and other venomous animals contain concentrates of biologically active substances developed to block vital physiological and biochemical functions of the victims. These have contrasting human health concerns, provide important pharmacological raw material and pose a serious threat to human life and health in tropical and subtropical regions. Because only occasional and minor quantities of venom are introduced into the human organism with a scorpion sting and their mortal effect is an acute phenomenon these substances are unknown to the immune defense system and thus no immunity has appeared against them during evolution. Antidotes prepared from animal anti-sera are effective against some species of scorpions but depend on the manufacturer and the availability of product to the medical community. Although significant progress has been made in immunological studies of certain groups of toxins, few centers are dedicated to this research. Information is still insufficient to generate a comprehensive picture of the subject and to propose vaccines against venoms. A novel approach based on mimotopes selected from phage-displayed random peptide libraries show potential to impel further progress of toxin immunological studies and to provide putative vaccine resources. In this report we revise the "state of the art" in the field.
Collapse
Affiliation(s)
- Karlen G Gazarian
- Department of Molecular Biology and Biotechnology of Institute of Biomedical Research, Mexican National University (UNAM), Ciudad Universitaria, Circuito escolar s/n, Ciudad Universitaria, 04510 México DF, México.
| | | | | | | |
Collapse
|